Framework for Regulation of DAO-Funded Biotechnology Research

1. Introduction and Meaning

A Decentralized Autonomous Organization (DAO) is a blockchain-based organization in which members coordinate activities, pool financial resources, and make decisions through token-based voting, smart contracts, or other decentralized governance mechanisms. A DAO may finance biotechnology research, including drug discovery, genomic medicine, synthetic biology, rare-disease research, and clinical trials.

DAO-funded biotechnology research refers to scientific research supported by funds collected and allocated through decentralized organizations rather than exclusively through traditional companies, universities, or government agencies.

The principal regulatory challenge is that decentralized funding does not eliminate legal responsibility. Biotechnology research remains subject to applicable rules concerning human-subject protection, laboratory safety, intellectual property, data privacy, financial compliance, and drug development. The legal position of a DAO also depends on its organizational structure, jurisdiction, activities, and the role of its participants.

An effective regulatory framework must therefore combine blockchain governance with established biotechnology laws to ensure scientific integrity, public safety, financial transparency, and accountability.

2. Objectives of the Regulatory Framework

The framework should pursue the following objectives:

Research safety: Prevent unsafe experiments and unauthorized clinical research.

Financial transparency: Establish traceable funding sources and accountable expenditure.

Legal accountability: Identify responsible persons and entities despite decentralized decision-making.

Ethical compliance: Protect research participants and respect informed consent.

Data protection: Safeguard genomic, medical, and other sensitive research information.

Intellectual property protection: Clarify ownership of research outputs, patents, and licensing rights.

Public interest: Prevent misuse of biotechnology and ensure that research benefits are distributed fairly.

3. Essential Components of the Regulatory Framework

A. Legal Recognition and Organizational Accountability

A DAO should determine whether it operates through a company, nonprofit organization, foundation, partnership, or another legally recognized structure. Where appropriate, a legal entity can enter contracts, employ researchers, hold intellectual property, obtain permits, and assume liability.

A DAO should maintain clear records identifying its administrators, treasury controllers, research partners, and persons authorized to approve funding.

Decentralized governance should not be treated as an automatic exemption from ordinary legal obligations. Depending on the applicable law, liability may attach to the DAO's legal entity, operators, developers, fund managers, or other participants based on their actual roles and conduct.

B. Research Approval and Biosafety Compliance

Before allocating funds, a DAO should verify that the proposed research has the necessary institutional permissions, ethics approvals, and biosafety safeguards.

For research involving human participants, funders should confirm that the research institution has appropriate ethics review, informed-consent procedures, safety monitoring, and arrangements for reporting adverse events.

For research involving genetically modified organisms, pathogens, or other potentially hazardous biological materials, the project must comply with the applicable biosafety and environmental framework.

In India, relevant laws and instruments may include the Environment (Protection) Act, 1986, the Rules of 1989 concerning hazardous microorganisms and genetically engineered organisms, the New Drugs and Clinical Trials Rules, 2019, and applicable Indian Council of Medical Research ethical guidelines. The precise requirements depend on the research activity.

C. Financial Transparency and Anti-Money-Laundering Controls

DAO treasuries may receive cryptocurrency, token-sale proceeds, donations, or contributions from multiple jurisdictions. This creates risks involving anonymous funding, sanctions violations, money laundering, and undisclosed conflicts of interest.

A suitable framework should require:

Risk-based identity verification and due diligence where legally required.

Documentation of funding sources and transfers.

Auditable records of grants, research contracts, and expenditures.

Conflict-of-interest declarations by voters and project evaluators.

Screening and reporting procedures where applicable financial laws require them.

Blockchain transaction histories can support auditing, but they do not independently establish the identity of a donor or the legitimacy of a transaction.

D. Smart-Contract Governance and Accountability

Smart contracts may automatically release funds when milestones are achieved. However, a code-based decision cannot replace scientific, ethical, or regulatory judgment.

The DAO should establish independent review before funds are released for sensitive research. Smart contracts should contain safeguards against unauthorized transfers, fraudulent milestones, and conflicts between automated rules and legal obligations.

Important measures include code audits, multisignature treasury controls, emergency suspension procedures, documented voting rules, and dispute-resolution mechanisms.

E. Intellectual Property and Research Data

Funding agreements should specify who owns inventions, patents, laboratory results, biological materials, and software developed through DAO grants.

They should also clarify publication rights, licensing conditions, benefit-sharing obligations, and access to resulting treatments. Researchers must retain appropriate scientific independence and should not be pressured to suppress unfavorable findings.

Where genomic or health data are involved, the parties must establish lawful grounds for processing, access restrictions, security controls, retention periods, and procedures for cross-border transfers in accordance with applicable privacy law.

F. Independent Monitoring and Enforcement

A DAO should establish an independent scientific and ethics committee with authority to review projects, investigate misconduct, suspend funding, and recommend corrective action.

Periodic audits should examine both the financial trail and the scientific progress of funded projects. Funding should be suspended where approvals expire, serious safety concerns emerge, or material misrepresentations are discovered.

4. Important Case Laws

The following cases provide legal principles relevant to DAO-funded biotechnology research. They do not all concern biotechnology DAOs directly.

A. SEC v. W.J. Howey Co. (1946)

The United States Supreme Court established the investment-contract test commonly known as the Howey test. An arrangement may qualify as an investment contract where it involves an investment of money in a common enterprise with an expectation of profits derived from the efforts of others.

Relevance: If a biotechnology DAO issues tokens to finance research and promises financial returns, the token arrangement may fall within securities regulation, depending on its economic substance and the applicable law. Calling a token a governance token does not automatically exclude securities obligations.

B. SEC v. Ripple Labs, Inc. (S.D.N.Y. 2023)

In this decision, the US District Court for the Southern District of New York examined different categories of XRP transactions under securities law. The court's analysis distinguished transaction contexts rather than treating every distribution identically.

Relevance: DAO fundraising arrangements should be assessed according to how tokens are offered, marketed, and sold. A DAO financing biotechnology research may face securities-law obligations where its fundraising structure satisfies the relevant legal test. The decision is fact-specific and should not be read as a blanket exemption for token-based fundraising.

C. CFTC v. Ooki DAO (N.D. Cal. 2022)

The US District Court for the Northern District of California addressed the Commodity Futures Trading Commission's action against Ooki DAO and held that the DAO could be treated as a person under the Commodity Exchange Act for purposes of the proceedings.

Relevance: The case demonstrates that decentralized governance does not necessarily prevent legal proceedings against a DAO. Biotechnology DAOs should establish responsible legal structures, preserve governance records, and ensure that regulated activities comply with applicable law.

D. Loper Bright Enterprises v. Raimondo (2024)

The US Supreme Court overturned the Chevron doctrine of judicial deference to reasonable agency interpretations of ambiguous statutes.

Relevance: Regulatory agencies supervising DAO-funded research must act within their statutory authority. Sponsors and DAOs should carefully assess the governing legislation, regulations, and binding judicial decisions rather than assuming that every agency interpretation automatically determines the law.

E. Jacob Puliyel v. Union of India (2013)

The Supreme Court of India considered clinical-trial regulation and safeguards for research participants in litigation concerning clinical trials and drug regulation.

Relevance: DAO-funded research conducted in India must respect applicable participant-protection requirements. Decentralized funding cannot displace the legal responsibilities of sponsors, investigators, research institutions, or ethics committees.

5. Regulatory Position in India and International Practice

In India, the framework depends on the activity being funded. Relevant legislation may include the Companies Act, 2013; the Securities Contracts (Regulation) Act, 1956; applicable provisions of the Income-tax Act, 1961; the Prevention of Money Laundering Act, 2002, where applicable; the Digital Personal Data Protection Act, 2023, subject to its applicable commencement and rules; and biotechnology, environmental, and clinical-trial regulations.

India does not have a single comprehensive statutory regime specifically designed for all DAOs. Therefore, their legal treatment must be assessed under the existing laws applicable to their structure and activities.

Internationally, the United States applies securities, commodities, research, and biotechnology laws according to the circumstances. The European Union's Markets in Crypto-Assets Regulation (MiCA) may be relevant to certain crypto-asset activities, although its scope and exclusions must be examined carefully. Neither a DAO label nor the use of blockchain automatically removes ordinary research and financial obligations.

6. Major Challenges and Practical Solutions

7. Conclusion

The regulation of DAO-funded biotechnology research requires an integrated framework that combines decentralized governance with established legal safeguards. Effective oversight should address organizational accountability, research ethics, biosafety, financial compliance, token regulation, intellectual property, data privacy, and independent auditing.

The cited judicial decisions establish important principles concerning investment contracts, DAO accountability, regulatory authority, and clinical-trial safeguards. They do not establish a dedicated legal regime for biotechnology DAOs. Ultimately, decentralized funding should facilitate scientific innovation without weakening the legal protections owed to research participants, the public, and the scientific community.